These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31521530)

  • 1. Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma.
    Silagy AW; Flynn J; Mano R; Blum KA; Marcon J; DiNatale RG; Sanchez A; Carlo MI; Motzer RJ; Coleman JA; Russo P; Ostrovnaya I; Chen YB; Hakimi AA
    Urol Oncol; 2019 Nov; 37(11):811.e9-811.e16. PubMed ID: 31521530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
    Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
    Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF
    Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status.
    Ohno Y; Nakashima J; Ohori M; Tanaka A; Hashimoto T; Gondo T; Hatano T; Tachibana M
    Int J Clin Oncol; 2014 Feb; 19(1):139-45. PubMed ID: 23299279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience.
    Silagy AW; Mano R; Blum KA; DiNatale RG; Marcon J; Tickoo SK; Reznik E; Coleman JA; Russo P; Hakimi AA
    Urology; 2020 Feb; 136():169-175. PubMed ID: 31726184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma.
    Mano R; Flynn J; Blum KA; Silagy AW; DiNatale RG; Marcon J; Wang A; Sanchez A; Coleman JA; Russo P; Ostrovnaya I; Hakimi AA
    Urol Oncol; 2019 Dec; 37(12):916-923. PubMed ID: 31590969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.
    Jiang W; Shou J; Shi H; Wen L; Zhang H; Zheng S; Li C; Ma J
    Technol Cancer Res Treat; 2021; 20():15330338211019507. PubMed ID: 34032149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.
    Peyton CC; Abel EJ; Chipollini J; Boulware DC; Azizi M; Karam JA; Margulis V; Master VA; Matin SF; Raman JD; Sexton WJ; Wood CG; Spiess PE
    Eur Urol Focus; 2020 Jan; 6(1):104-111. PubMed ID: 30206003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
    Fiala O; Buti S; Bamias A; Massari F; Pichler R; Maruzzo M; Grande E; De Giorgi U; Molina-Cerrillo J; Seront E; Calabrò F; Myint ZW; Facchini G; Kopp RM; Berardi R; Kucharz J; Vitale MG; Pinto A; Formisano L; Büttner T; Messina C; Monteiro FSM; Battelli N; Kanesvaran R; Büchler T; Kopecký J; Santini D; Giudice GC; Porta C; Santoni M
    Target Oncol; 2024 Jul; 19(4):587-599. PubMed ID: 38704759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
    Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
    Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy.
    Viers BR; Houston Thompson R; Boorjian SA; Lohse CM; Leibovich BC; Tollefson MK
    Urol Oncol; 2014 Nov; 32(8):1277-84. PubMed ID: 25017696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable?
    Shuch B; Said J; La Rochelle JC; Zhou Y; Li G; Klatte T; Kabbinaavar FF; Pantuck AJ; Belldegrun AS
    J Urol; 2009 Nov; 182(5):2164-71. PubMed ID: 19758641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database.
    Park CL; Moria FA; Ghosh S; Wood L; Bjarnason GA; Bhindi B; Heng DYC; Castonguay V; Pouliot F; Kollmannsberger CK; Bosse D; Basappa NS; Finelli A; Fallah-Rad N; Breau RH; Lalani AA; Tanguay S; Graham J; Saleh RR
    Curr Oncol; 2024 Aug; 31(8):4704-4712. PubMed ID: 39195334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.
    Abel EJ; Spiess PE; Margulis V; Master VA; Mann M; Zargar-Shoshtari K; Borregales LD; Sexton WJ; Patil D; Matin SF; Wood CG; Karam JA
    J Urol; 2017 Aug; 198(2):281-288. PubMed ID: 28268170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.
    DiNatale RG; Xie W; Becerra MF; Silagy AW; Attalla K; Sanchez A; Mano R; Marcon J; Blum KA; Benfante NE; Voss MH; Motzer RJ; Coleman J; Choueiri TK; Reznik E; Russo P; Heng DYC; Hakimi AA
    Eur Urol Oncol; 2020 Feb; 3(1):47-56. PubMed ID: 31735646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
    Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clear cell and non-clear cell renal cell carcinoma in young adults: clinicopathological features, survival outcomes and prognostic factors.
    Xue Z; Tang S; Ou J; Fang Y; Qiu M; Hong K; Tian X; Zhang H; Liu C; Ma L; Zhang S
    World J Urol; 2024 May; 42(1):364. PubMed ID: 38819448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
    Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
    Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.